Literature DB >> 3133814

Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).

C Kluft1, A F Jie, D C Rijken, J H Verheijen.   

Abstract

Circadian fluctuation in blood fibrinolytic activity was studied in 10 volunteers in the day-time period at 09.00, 12.00 and 15.00 h. Activity of tissue-type plasminogen activator (t-PA) was found to increase from 09.00 to 15.00 h in accordance with known results with global assays of blood activity. Also, activity and antigen of plasminogen activator inhibitor 1 (PAI-1) and antigen of t-PA showed fluctuations but with an opposite pattern to that of t-PA activity, with highest levels in the morning and lowest ones in the afternoon. Activity of a reversible t-PA inhibitor was constant. The discordance between fluctuations in antigen and in activity of t-PA is attributed to the inhibitory effect of PAI-1 on t-PA activity. It is concluded that the appearance into the blood of t-PA and PAI-1 shows a daytime fluctuation with a similar pattern, suggesting a co-ordinated circadian fluctuation in production of both proteins by endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133814

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle.

Authors:  Frank A J L Scheer; Steven A Shea
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

Review 3.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

4.  Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.

Authors:  Ken Yajima; Akira Shimada; Hiroshi Hirose; Yoichi Oikawa; Satoru Yamada; Shu Meguro; Junichiro Irie; Seiko Irie
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 5.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

6.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

7.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

8.  Effect of moderate dose of alcohol with evening meal on fibrinolytic factors.

Authors:  H F Hendriks; J Veenstra; E J Velthuis-te Wierik; G Schaafsma; C Kluft
Journal:  BMJ       Date:  1994-04-16

9.  Effect of growth hormone on plasminogen activator and inhibitor activity in rat.

Authors:  P Bubber; A Sharma; A Chauhan; D D Bansal
Journal:  Indian J Clin Biochem       Date:  2012-08-28

10.  Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.

Authors:  A B Bridges; M McLaren; N A Scott; T H Pringle; G P McNeill; J J Belch
Journal:  Br Heart J       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.